<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764218</url>
  </required_header>
  <id_info>
    <org_study_id>DGS2001/0398</org_study_id>
    <nct_id>NCT00764218</nct_id>
  </id_info>
  <brief_title>Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome</brief_title>
  <acronym>SAS-HTA</acronym>
  <official_title>Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome : Role of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with obstructive sleep apnea syndrome have permanent variations of their hemodynamic
      parameters during the night : heart rate, arterial blood pressure, cardiac output. This is
      due to the repetition of respiratory events (obstructive apnea and hypopnea) leading to
      frequent micro-arousals. These disorders have several consequences : hypertension,
      NO-dependent vasodilatation impairment, baroreceptor reflex impairment, insulin resistance
      and other cardiovascular impairments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of the study is to characterize the cardiovascular phenotype of patients with
      obstructive sleep apnea syndrome, relative to the presence of hypertension or not.
      Hypertension should not have been previously treated. 2 groups of apneic patients (SAS+HTA+
      and SAS+HTA-) will be compared together, referred to group of non apneic but hypertensive
      patients (SAS-HTA+) and non apneic / non hypertensive patients (SAS-HTA-).

      Apneic and hypertensive patients may have a sympathetic nervous system activation and a much
      more important vascular and baroreceptor reflex impairment, than non apneic but hypertensive
      patients.

      During the study, a second visit as control will be done for apneic patients only, 3 to 6
      months after SAS treatment setting.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">December 2003</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular phenotype study in patients with non treated obstructive sleep apnea syndrome</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>characterization of arterial blood pressure, sympathetic activity, functional and morphological cardiovascular modifications. Effect of a treatment of obstructive sleep apnea syndrome on those different parameters.</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>SAS+HTA+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obstructive sleep apnea syndrome and hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS+HTA-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non hypertensive patients with obstructive sleep apnea syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS-HTA+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypertensive patients without obstructive sleep apnea syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS-HTA-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non hypertensive patients without obstructive sleep apnea syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positive airway pressure treatment</intervention_name>
    <description>Positive airway pressure treatment as long as necessary</description>
    <arm_group_label>SAS+HTA+</arm_group_label>
    <arm_group_label>SAS+HTA-</arm_group_label>
    <other_name>CPAP treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No positive airway pressure treatment</intervention_name>
    <description>No treatment</description>
    <arm_group_label>SAS-HTA+</arm_group_label>
    <arm_group_label>SAS-HTA-</arm_group_label>
    <other_name>No CPAP treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with or without obstructive sleep apnea syndrome (AHI &gt; 15)

          -  patients with or without hypertension

        Exclusion Criteria:

          -  known or expected secondary hypertension

          -  pathologies with consequences on arterial blood pressure regulation: Parkinson's
             disease, patients with renal or cardiac graft, severe heart failure

          -  drugs with consequences on arterial blood pressure regulation : vasoconstrictors,
             vasodilatators, béta-agonists, antagonists, nitrites, theophylline, dipyridamol,
             sildenafil, immunosuppressors, IMAO, neuroleptics, tricyclic antidepressants,
             corticoids or long-term oral (&gt;10 days) non steroidal anti-inflammatory drugs,
             oestroprogestative treatments

          -  atrial fibrillation, frequent extrasystoles (&gt; or = to 10/minute)

          -  bedridden patients

          -  night shift workers

          -  surgical or carotid stenting history

          -  subjects unwilling or unable to provide written, signed and dated informed consent

          -  patient previously treated for obstructive sleep apnea syndrome (positive airway
             pressure, forward mandible prosthesis, maxillofacial surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe JB BAGUET, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe JB BAGUET, PhD</last_name>
    <phone>00330476764226</phone>
    <phone_ext>64226</phone_ext>
    <email>JBaguet@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Louis JP PEPIN, PhD</last_name>
    <phone>00330476768473</phone>
    <phone_ext>68473</phone_ext>
    <email>JPepin@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology and hypertension service</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe JB BAGUET, PhD</last_name>
      <phone>0033476764226</phone>
      <phone_ext>64226</phone_ext>
      <email>JBaguet@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Louis JP PEPIN, PhD</last_name>
      <phone>0033476768473</phone>
      <phone_ext>68473</phone_ext>
      <email>JPepin@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pankow W, Nabe B, Lies A, Becker H, Köhler U, Kohl FV, Lohmann FW. Influence of sleep apnea on 24-hour blood pressure. Chest. 1997 Nov 5;112(5):1253-8.</citation>
    <PMID>9367465</PMID>
  </reference>
  <reference>
    <citation>Portaluppi F, Provini F, Cortelli P, Plazzi G, Bertozzi N, Manfredini R, Fersini C, Lugaresi E. Undiagnosed sleep-disordered breathing among male nondippers with essential hypertension. J Hypertens. 1997 Nov;15(11):1227-33.</citation>
    <PMID>9383171</PMID>
  </reference>
  <reference>
    <citation>Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992 Sep;10(9):1025-31.</citation>
    <PMID>1328361</PMID>
  </reference>
  <reference>
    <citation>Strohl KP, Novak RD, Singer W, Cahan C, Boehm KD, Denko CW, Hoffstem VS. Insulin levels, blood pressure and sleep apnea. Sleep. 1994 Oct;17(7):614-8.</citation>
    <PMID>7846459</PMID>
  </reference>
  <reference>
    <citation>Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension. 1992 Jan;19(1 Suppl):I61-6. Review.</citation>
    <PMID>1730456</PMID>
  </reference>
  <reference>
    <citation>Carlson JT, Hedner JA, Sellgren J, Elam M, Wallin BG. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 1996 Nov;154(5):1490-6.</citation>
    <PMID>8912770</PMID>
  </reference>
  <reference>
    <citation>Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11;342(19):1378-84.</citation>
    <PMID>10805822</PMID>
  </reference>
  <reference>
    <citation>Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000 Apr 12;283(14):1829-36. Erratum in: JAMA 2002 Oct 23-30;288(16):1985.</citation>
    <PMID>10770144</PMID>
  </reference>
  <reference>
    <citation>Baguet JP, Mallion JM, Moreau-Gaudry A, Noirclerc M, Péoc'h M, Siché JP. Relationships between cardiovascular remodelling and the pulse pressure in never treated hypertension. J Hum Hypertens. 2000 Jan;14(1):23-30.</citation>
    <PMID>10673727</PMID>
  </reference>
  <verification_date>January 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>September 30, 2008</last_update_submitted>
  <last_update_submitted_qc>September 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>BAGUET Jean-Philippe, PhD</name_title>
    <organization>University Hospital Grenoble</organization>
  </responsible_party>
  <keyword>Obstructive sleep apnea syndrome</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular phenotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

